The latest news on next-generation sequencing.
The firm said that it planned to lay off its oncology sales team in order to focus on women's health, despite launching an oncology business unit last spring.
The investment bank set a price target of $18.00 for shares of the molecular diagnostics company.
The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL.
Illumina plans to speed up the process of making Grail an independent company and will no longer have representation on its board of directors.
Natera alleges that Bio-Reference broke a contract by promoting a NIPS test based on Illumina technology over Panorama.
The annual list includes guidelines that would clarify regulations for garnering premarket approval or clearance of devices and diagnostics, particularly next-generation sequencing tests.
Palmetto GBA revised a final LCD for comprehensive genomic profiling in lung cancer, and issued similar draft determinations in other cancers.
Under the PIPseq program, Columbia University researchers sequenced the exome, transcriptome, or a gene panel in tumors of 101 high-risk pediatric cancer patients.
The panel's decisions could change the codes diagnostic companies use to bill payors for these tests, which could affect revenue.
A new study shows that combining size-based and count-based analysis helps determine whether a copy number aberration originates in the mother, fetus, or both.